HOW WE CAN HELP YOU

Our Services for Professional Investors:

  • Biotech and Pharmaceutical Asset Ratings
  • Strategic Portfolio Support
  • Recommendation of Assets for Your Specific Needs
  • Competitive Landscaping of Your Areas of Interest
  • Second Investment Opinion and Due Diligence
LEARN MORE

ASSET RATINGS

Biotech Investments is a leader in pharmaceutical asset ratings. Our unique Asset Rating Simulator is an elegant tool to simulate the medical potential of drug candidates.

Our Asset Rating Reports describe the rating of a specific asset in full detail, including a critical appraisal on the MoA, preclinical and clinical data, trial design, and a competitor overview.

Get an Expert Opinion from our independent medical experts and discuss opportunities and risks of a specific asset in the context of the whole clinical pipeline.

LEARN MORE

ON-DEMAND ASSET RATINGS

Biotech Investments also offers On-Demand Asset Ratings for all therapeutic areas, including neurology, immunology, oncology, ophthalmology, rare disease, among many others.

Discover interesting new investment opportunities or use our analyses for due diligence or a second investment opinion. On-Demand Asset Rating Reports can be combined with an independent medical Expert Opinion.

GET EXPERT OPINION

BIOTECH AND PHARMA NEWS

April 19, 2024
SYNLAB AG

SYNLAB AG: SYNLAB affected by cyber-attack in Italy

View Article
April 19, 2024
Vita 34 AG

Vita 34 closes 2023 with significantly better results than expected based on preliminary figures

View Article
April 19, 2024
Biotest AG

Biotest AG opens 12th plasma collection centre in Germany

View Article
MORE NEWS